ArticleFrontiers in immunology2026
Novel B-Cell targeting therapy with subcutaneous ofatumumab in AQP4-IgG-seronegative Neuromyelitis Optica Spectrum Disorders: efficacy and personalized dosing.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: AQP4-IgG-seronegative Neuromyelitis Optica Spectrum Disorders (AQP4-IgG-seronegative NMOSD) represent a distinct and rare subtype of Neuromyelitis Optica Spectrum Disorders (NMOSD). Diagnosis and management of this condition pose significant challenges in clinical practice. Here, we present two cases of AQP4-IgG-seronegative NMOSD, which demonstrated a favorable response to personalized ofatumumab (OFA) therapy. Methods: Two patients, confirmed negative for both AQP4-IgG and MOG-IgG by cell-based assay methods and meeting the diagnostic criteria for AQP4-IgG-negative NMOSD according to the 2015 international criteria were treated with monthly subcutaneous OFA (20 mg). Clinical status was monitored using the Expanded Disability Status Scale (EDSS), B-cell depletion (CD19+%), MRI, and serum neurofilament light chain (NfL). Results: Both patients (a 13-year-old male and a 31-year-old female) had severe disability (EDSS 6.5 and 5.5, respectively) and poor response to initial steroids/IVIG. After OFA initiation, both achieved rapid and sustained B-cell depletion (CD19+% 0.00-0.11%). Symptoms remained stable and gradually improved, imaging showing marked reduction or resolution of lesions and EDSS scores decreasing by ≥3 points (to 2.0 in both patients) over 18-20 months of follow-up. No clinical relapses or serious adverse events (e.g., infections, significant IgG reduction) occurred. After 12 months of monthly dosing, the interval was successfully extended to every two months in both patients while maintaining efficacy and B-cell depletion. Discussion: Subcutaneous OFA demonstrated sustained efficacy and a favorable safety profile as a long-term therapy for AQP4-IgG-seronegative NMOSD in this case series. It facilitated significant functional recovery, prevented relapses, and enabled personalized, extended dosing intervals. These preliminary findings support OFA as a promising, convenient therapeutic option for AQP4-IgG-seronegative NMOSD, meriting further investigation in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.